CN1384816A - 多晶型形式的盐酸舍曲林 - Google Patents

多晶型形式的盐酸舍曲林 Download PDF

Info

Publication number
CN1384816A
CN1384816A CN00815052A CN00815052A CN1384816A CN 1384816 A CN1384816 A CN 1384816A CN 00815052 A CN00815052 A CN 00815052A CN 00815052 A CN00815052 A CN 00815052A CN 1384816 A CN1384816 A CN 1384816A
Authority
CN
China
Prior art keywords
sertraline hydrochloride
sertraline
polymorph
hydrochloride
characteristic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00815052A
Other languages
English (en)
Chinese (zh)
Inventor
P·A·范德沙尔夫
F·施瓦岑巴赫
H·J·基尔纳
M·施策拉吉维茨
C·马科利
A·波克哈德
R·彼得
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Schweiz AG
Original Assignee
Ciba Spezialitaetenchemie Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8243113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1384816(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Spezialitaetenchemie Holding AG filed Critical Ciba Spezialitaetenchemie Holding AG
Publication of CN1384816A publication Critical patent/CN1384816A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN00815052A 1999-10-29 2000-10-23 多晶型形式的盐酸舍曲林 Pending CN1384816A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99810981.3 1999-10-29
EP99810981 1999-10-29

Publications (1)

Publication Number Publication Date
CN1384816A true CN1384816A (zh) 2002-12-11

Family

ID=8243113

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00815052A Pending CN1384816A (zh) 1999-10-29 2000-10-23 多晶型形式的盐酸舍曲林

Country Status (17)

Country Link
US (2) US6872853B1 (https=)
EP (1) EP1224160B1 (https=)
JP (1) JP2003513062A (https=)
CN (1) CN1384816A (https=)
AR (1) AR026293A1 (https=)
AT (1) ATE409684T1 (https=)
AU (1) AU1386301A (https=)
CA (1) CA2387135A1 (https=)
DE (1) DE60040406D1 (https=)
HU (1) HUP0203559A3 (https=)
IL (2) IL149050A0 (https=)
MX (1) MXPA02004255A (https=)
MY (1) MY141509A (https=)
TR (1) TR200201146T2 (https=)
TW (1) TWI260315B (https=)
WO (1) WO2001032601A1 (https=)
ZA (1) ZA200203254B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105061217A (zh) * 2015-06-30 2015-11-18 徐静 枸橼酸舍曲林的2种晶型及其制备方法
CN112552188A (zh) * 2020-12-17 2021-03-26 山西仟源医药集团股份有限公司 盐酸舍曲林晶型i的制备方法
CN113588626A (zh) * 2021-08-24 2021-11-02 上海师范大学 一种苯丙氨酸对映体的拉曼光谱检测方法

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500987B1 (en) * 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
HK1040979A1 (zh) * 1998-11-27 2002-06-28 Teva Pharmaceutical Industries Ltd. 盐酸舍曲林多晶型物
EP1632474A1 (en) * 1998-11-27 2006-03-08 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
US7442838B2 (en) * 1999-10-29 2008-10-28 Ciba Specialty Chemicals Corp. Polymorphic forms of sertraline hydrochloride
US20050119351A1 (en) * 1999-10-29 2005-06-02 Van Der Schaaf Paul A. Polymorphic forms of sertraline hydrochloride
EP1774965A3 (en) * 1999-12-21 2007-10-10 Teva Pharmaceutical Industries Ltd Novel sertraline hydrochloride polymorph, processes for preparing them, compositions containing them and methods of using them
ES2281374T3 (es) * 1999-12-21 2007-10-01 Teva Pharmaceutical Industries Ltd. Nuevos polimorfos de hidrocloruro de sertralina, procedimientos para su preparacion, composiciones que los contienen y metodos para su utilizacion.
IN192343B (https=) * 2000-05-26 2004-04-10 Ranbaxy Lab Ltd
CA2448279A1 (en) 2001-05-31 2002-12-05 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
AU2003251290A1 (en) * 2002-04-29 2003-11-17 Teva Pharmaceutical Industries Ltd. Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
MXPA04011375A (es) * 2002-06-27 2005-02-14 Interdigital Tech Corp Controlador de red de radio para intercambio de informacion de equipo.
WO2005000786A1 (en) 2003-05-23 2005-01-06 Transform Pharmaceuticals, Inc. Sertraline compositions
JP4791970B2 (ja) 2003-11-04 2011-10-12 シプラ・リミテッド 選択的セロトニン再取込み阻害剤の多形体の製造方法
EP1711493A2 (en) * 2004-02-06 2006-10-18 CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement Crystalline forms of zolmitriptan
EP1893559A2 (en) * 2005-06-09 2008-03-05 Teva Pharmaceutical Industries Ltd Process for preparation of sertraline hydrochloride form i
US7518019B2 (en) 2006-06-01 2009-04-14 Hetero Drugs Limited Processes for preparing sertraline hydrochloride crystalline forms
CA2594198A1 (en) * 2007-07-20 2009-01-20 Apotex Pharmachem Inc. A novel process for the preparation of sertraline hydrochloride form ii
US9993793B2 (en) 2010-04-28 2018-06-12 The Procter & Gamble Company Delivery particles
US9186642B2 (en) 2010-04-28 2015-11-17 The Procter & Gamble Company Delivery particle
WO2012138710A2 (en) 2011-04-07 2012-10-11 The Procter & Gamble Company Personal cleansing compositions with increased deposition of polyacrylate microcapsules
WO2012138696A2 (en) 2011-04-07 2012-10-11 The Procter & Gamble Company Shampoo compositions with increased deposition of polyacrylate microcapsules
WO2012138690A2 (en) 2011-04-07 2012-10-11 The Procter & Gamble Company Conditioner compositions with increased deposition of polyacrylate microcapsules
US12486478B2 (en) 2020-10-16 2025-12-02 The Procter & Gamble Company Consumer products comprising delivery particles with high core:wall ratios
US12227720B2 (en) 2020-10-16 2025-02-18 The Procter & Gamble Company Consumer product compositions with at least two encapsulate populations
CN116323893A (zh) 2020-10-16 2023-06-23 宝洁公司 包含包封物群体的消费产品组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US5082970A (en) 1991-03-06 1992-01-21 Pfizer Inc. Process for recycling amine isomer
GB9114947D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5734083A (en) 1996-05-17 1998-03-31 Torcan Chemical Ltd. Sertraline polymorph
HU222341B1 (hu) 1996-12-18 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Eljárás sertralin előállítására és az eljárásban alkalmazott intermedier
EP0928784B1 (en) 1997-12-11 2002-06-12 TORCAN CHEMICAL Ltd Sertraline polymorph having improved water solubility
ES2217748T3 (es) 1998-03-18 2004-11-01 Ciba Specialty Chemicals Holding Inc. Procedimiento para la hidrogenacin catalitica cis-selectiva de ciclohexilidenaminas.
JP2000026378A (ja) 1998-07-03 2000-01-25 Sumika Fine Chemicals Co Ltd 塩酸セルトラリンの製法
HK1040979A1 (zh) 1998-11-27 2002-06-28 Teva Pharmaceutical Industries Ltd. 盐酸舍曲林多晶型物
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
ES2281374T3 (es) 1999-12-21 2007-10-01 Teva Pharmaceutical Industries Ltd. Nuevos polimorfos de hidrocloruro de sertralina, procedimientos para su preparacion, composiciones que los contienen y metodos para su utilizacion.

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105061217A (zh) * 2015-06-30 2015-11-18 徐静 枸橼酸舍曲林的2种晶型及其制备方法
CN112552188A (zh) * 2020-12-17 2021-03-26 山西仟源医药集团股份有限公司 盐酸舍曲林晶型i的制备方法
CN112552188B (zh) * 2020-12-17 2023-07-28 山西仟源医药集团股份有限公司 盐酸舍曲林晶型i的制备方法
CN113588626A (zh) * 2021-08-24 2021-11-02 上海师范大学 一种苯丙氨酸对映体的拉曼光谱检测方法
CN113588626B (zh) * 2021-08-24 2024-05-24 上海师范大学 一种苯丙氨酸对映体的拉曼光谱检测方法

Also Published As

Publication number Publication date
US6872853B1 (en) 2005-03-29
MXPA02004255A (es) 2002-10-17
AU1386301A (en) 2001-05-14
US20040132828A1 (en) 2004-07-08
MY141509A (en) 2010-05-14
EP1224160B1 (en) 2008-10-01
HUP0203559A3 (en) 2008-01-28
IL149050A (en) 2007-03-08
IL149050A0 (en) 2002-11-10
AR026293A1 (es) 2003-02-05
US6939992B2 (en) 2005-09-06
CA2387135A1 (en) 2001-05-10
TWI260315B (en) 2006-08-21
JP2003513062A (ja) 2003-04-08
ZA200203254B (en) 2003-07-22
HUP0203559A2 (hu) 2003-03-28
WO2001032601A1 (en) 2001-05-10
EP1224160A1 (en) 2002-07-24
DE60040406D1 (de) 2008-11-13
ATE409684T1 (de) 2008-10-15
TR200201146T2 (tr) 2004-12-21

Similar Documents

Publication Publication Date Title
CN1384816A (zh) 多晶型形式的盐酸舍曲林
CN1753874A (zh) 可用作肾上腺素受体激动剂的 5－′( r )－2－( 5 , 6－二乙基－茚满－2－基氨基)－1－羟基－乙基－8－羟基－(1h)－喹啉－2－酮盐的制备方法
CN1275126A (zh) 2－(3－氰基－4－异丁氧基苯基)－4－甲基－5－噻唑甲酸的多晶型体及其制备方法
CN1867564A (zh) 氨基巴豆基化合物的制备方法
CN1845917A (zh) 3－[(2－{[4－(已氧基羰基氨基－亚氨基－甲基)－苯氨基]－甲基}－1－甲基－1 h－苯并咪唑－5－羰基)－吡啶－2－基－氨基]－丙酸乙酯－甲磺酸酯及其作为药物的用途
CN1378448A (zh) 多晶型托拉塞米
CN1132829C (zh) N－乙酰基神经氨酸衍生物结晶及其制备方法
CN1777613A (zh) 奥氮平盐酸盐新的多晶型
CN1173928C (zh) 制备(1r,2s,4r)-(-)-2-[(2′-({n,n-二甲基氨基}乙氧基)]-2-[苯基]-1,7,7三[甲基]-二环[2.2.1]庚烷及其可药用酸加成盐的方法
CN1934108A (zh) 齐拉西酮碱的多晶型b2
CN1922188A (zh) 氯吡格雷之药学可接受的盐
CN1283625C (zh) 纯化的lasofoxifene及通过重结晶纯化外消旋lasofoxifene的方法
CN1114592C (zh) 奥沙奈丹的晶型
CN1191529A (zh) 环状化合物的生产方法
CN1225625A (zh) α－氨基酸酰胺,其制备方法及其治疗用途
CN1639111A (zh) 制备2－氨基茚满衍生物的方法
CN1161324C (zh) 黄色多晶型的5-氨基-2,4,6-三碘-n,n'-双(2,3-二羟基丙基)间苯二甲酰胺
CN1030077A (zh) 法莫丁啶多晶型物及其制备方法
CN1993369A (zh) 特比萘芬及其衍生物的合成方法
CN1668572A (zh) 制备苯氧基乙酸衍生物的中间体及其使用方法
CN1216036C (zh) 手性氨基醇配体及其在端炔对亚氨的不对称加成中的应用
CN1768057A (zh) 罗格列酮马来酸盐多晶型物的制备方法
CN1190418C (zh) 制备偏端霉素衍生物的方法
CN1244543C (zh) 制备4－(烷基)－3－烷氧基－苯胺型化合物的方法
EA011763B1 (ru) Способы получения венлафаксина и формы i венлафаксина гидрохлорида

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication